HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia Continues Down OTC Path For CBD, But Will It Widen Access?

Executive Summary

[Link Fixed] Australia's Ministry of Health has provisionally switched CBD from prescription-only to OTC status to widen access in the absence of any safety concerns and to encourage companies to undertake much-needed clinical trials to prove efficacy for CBD in low doses. However, switch expert Natalie Gauld thinks these expensive trials, and therefore approved Australian OTC CBD products, may not be forthcoming.

You may also be interested in...



Industry Welcomes Australia’s OTC Drug Approach To Low-Dose CBD

Australia's Therapetics Goods Administration finalizes its decision to regulate low-dose CBD as an OTC medicine, raising the maximum daily dose to 150mg. The move is welcomed by the country's self-care industry. 

If Safety Data Open Door In US, Cannabinoids’ Lawful Use In Supplements At Least A Year Off

At FDLI annual meeting, attorneys cast doubt on CBD rules outlook. Paul Joseph says regulations are at least a year away while Jonathan Havens doubts FDA is even working on regulations, including GMPs, because it is still asking industry for specific safety details.

Waiting For Cannabidiol Guidance? US FDA Reminds Industry Of ‘Many Other Requirements’

Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.

Related Content

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel